Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects
Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 2. To Establish the Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects
1 other identifier
interventional
40
1 country
1
Brief Summary
The study is aimed at establishing the contribution of wine components on hydroxytyrosol body concentrations and biological effects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started May 2011
Typical duration for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2011
CompletedFirst Submitted
Initial submission to the registry
February 11, 2013
CompletedFirst Posted
Study publicly available on registry
February 13, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2013
CompletedJuly 24, 2014
July 1, 2014
2.3 years
February 11, 2013
July 23, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hydroxytyrosol biological fluids concentrations
Hydroxytyrosol concentrations in plasma and urine
0-24h after administration
Secondary Outcomes (10)
Ethanol concentration
0-6h after administration
Subjective drunkenness
0-6h after administration
Vital signs
0-24h after administration
Ethanol metabolites concentrations
0-24h after administration
Dopamine metabolites concentrations
0-24h after administration
- +5 more secondary outcomes
Study Arms (4)
Water
PLACEBO COMPARATORLemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
Alcoholized wine
ACTIVE COMPARATORWine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study. Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.
De-alcoholized wine
PLACEBO COMPARATORWine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
Ethanol
ACTIVE COMPARATOREthanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study. Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol. Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water.
Interventions
Eligibility Criteria
You may qualify if:
- Understanding and accepting the study procedures and signing the informed consent.
- Male and female volunteers aged 18 to 55 years. No fixed sex ratio has been established.
- Clinical history and physical examination demonstrating no organic or psychiatric disorders.
- The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- The body mass index (BMI=weigh/height2) will range from 19 to 25 kg/m2, and the weight from 50 to 100 kg. 25-27 could be accepted.
- Women with regular menstrual cycle of 26-32 days.
- Subjects socially drinking and who had ingested wine at least once.
You may not qualify if:
- History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
- History or clinical evidence of psychiatric disorders, alcoholism, drug abuse, or regular use of psychoactive drugs.
- Blood donation in the previous 8 weeks or participation in other clinical trials with drugs in the previous 12 weeks.
- Having suffered any organic disease or major surgery in the three months prior to the study start.
- Subjects with intolerance or serious adverse reactions to ethanol.
- Taking more than 20 g of alcohol a day in women and more than 30 g in men.
- Taking more than 5 coffees, teas, cola drinks or other stimulating drinks or with xanthines daily in the 3 months prior to the study start.
- Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
- Smokers or ex-smokers of less than one year.
- Subjects with positive serology to Hepatitis B, C or HIV.
- Pregnant or nursing women or positive pregnancy test in urine. Women not undertaking to follow reliable contraceptive measures during the study (such as abstinence, hormonal contraceptives, intrauterine devices, double-barrier methods or vasectomised partner).
- Women with amenorrhea or premenstrual syndrome of moderate or severe intensity.
- Nonsteroidal anti-inflammatory drugs, antioxidants or vitamins consumption in the last 2 weeks.
- Total cholesterol \>6.00 mmol/l (240 mg/dl) or triglycerides \>2.26 mmol/l (200 mg/dl).
- Vegetarians or subjects following aberrant diets.
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Parc de Salut Marlead
- Fundacion IMIMcollaborator
Study Sites (1)
Parc de Salut Mar
Barcelona, Barcelona, 08003, Spain
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Magí Farré, MD, PhD
Parc de Salut Mar
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 11, 2013
First Posted
February 13, 2013
Study Start
May 1, 2011
Primary Completion
September 1, 2013
Study Completion
September 1, 2013
Last Updated
July 24, 2014
Record last verified: 2014-07